Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria by Tang et al

We appreciate the comments by Tang et al1 in response to the publication of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) antiphospholipid syndrome (APS) classification criteria.2 3 We were interested to read about their study describing the performance of the classification criteria in 965 potential APS patients of Asian descent in China. Compared with their ‘gold standard’ involving clinical assessment of each potential APS case by two experienced rheumatologists, the authors report a specificity of 98% (95% confidence interval (CI) 97% to 99%) and sensitivity of 82% (95% CI 78% to 85%), comparable to the findings from our final validation cohort (specificity 99% (95% CI 98% to 100%), sensitivity 84% (95% CI 77% to 91%)). Similar to our findings, the authors report a lowered specificity of 90% (95% CI 87% to 92%) when using the revised Sapporo APS...
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Correspondence response Source Type: research